Role and mechanism of circ-PRKCI in hepatocellular carcinoma

Table 1 Primers used for the quantitative real-time PCR and siRNA related experiments

Circ-PRKCI	F: 5‘-TAGCAGTTCCCCAATCCTTG-3'
	R: 5‘-CACAAATTCCCATCATTCCC-3'
GAPDH	F: 5‘-AGAAGGCTGGGGCTCATTTG-3'
	R: 5‘-AGGGGCCATCCACAGTCTTC-3'
U6	F: 5‘-AGGGGCCATCCACAGTCTTC-3'
	R: 5‘-AACGCTTCACGAATTTGCGT-3'
Circ-PRKCI siRNA-1	Sense: 5'-UGUUGAUUGGGAUAUGUUAUU-3'
	Antisense: 5'-UAACAUAUCCCAAUCAACAUU-3'
Circ-PRKCI siRNA-2	Sense: 5'-CCGAAAUGUUGAUUGGGAUTT-3'
	Antisense: 5'-AUCCCAAUCAACAUUUCGGTT-3'

Table 2 Characteristics of hepatocellular carcinoma patients and control subjects

Variable	Patients (n = 20)		Controls (n = 20)		1P-value
	n	%	n	%
Age (yr, mean ± SD)	63.5 ± 5.9		60.3 ± 7.8		0.68
Weight (kg, mean ± SD)	68.2 ± 6.3		67.1 ± 8.5		0.81
Gender
Male	11	55	12	60	0.79
Female	9	45	8	40
Depth of invasion
T1/T2	7	35
T3/T4	13	65
Lymph node metastasis
N0	11	55
N1/N2/N3	9	45
Distant metastasis
M0	8	40
M1	12	60
TNM stage
I/II	6	30
III/IV	14	70
Portal venous invasion
Yes	9	45
No	11	55

¹Independent-samples t-test and two-sided χ² test were used for comparison of selected variables between cases and controls.